Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension at World Sleep 2025
1. AVDL presented 17 abstracts on LUMRYZ at World Sleep 2025. 2. REFRESH study shows positive outcomes for LUMRYZ in narcolepsy patients. 3. LUMRYZ's once-nightly dosing improves adherence and patient experience. 4. Clinically meaningful improvements observed in excessive daytime sleepiness scores. 5. LUMRYZ gains Orphan Drug Exclusivity, enhancing market competitiveness.